Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Lowered by Wall Street Zen

Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Saturday, September 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $70.00.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock opened at $24.00 on Friday. The business’s 50-day simple moving average is $34.42 and its two-hundred day simple moving average is $30.90. The company has a market cap of $210.48 million, a PE ratio of -0.61 and a beta of 1.87. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $130.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, August 11th. The company reported ($3.86) earnings per share for the quarter, missing the consensus estimate of ($3.10) by ($0.76). The firm had revenue of $2.00 million for the quarter, compared to analysts’ expectations of $2.60 million. Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%. As a group, analysts predict that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $25,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Tonix Pharmaceuticals during the second quarter worth approximately $62,000. BNP Paribas Financial Markets purchased a new position in Tonix Pharmaceuticals during the second quarter worth approximately $65,000. Finally, Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals during the fourth quarter worth approximately $66,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.